Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

Pratap Neelakantan, Gareth Gerrard, Claire Lucas, Dragana Milojkovic, Philippa May, Lihui Wang, Christos Paliompeis, Marco Bua, Alistair Reid, Katayoun Rezvani, Stephen O'Brien, Richard Clark, John Goldman, David Marin

Blood (2013) 121 (14): 2739–2742.

https://doi.org/10.1182/blood-2012-11-466037

Published: 2013

Includes: Supplemental data

Journal Articles

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Dragana Milojkovic, MD, Gareth Gerrard, PhD, Christos Paliompeis, Marco Bua, MD, Alistair Reid, PhD, Mary Alikian, Jamshid Khorashad, MD, PhD, John M Goldman, David Marin, Letizia Foroni, MD PhD, Jane F Apperley, MBChB, MD, FRCP, FRCPath

Blood (2011) 118 (21): 605.

https://doi.org/10.1182/blood.V118.21.605.605

Published: 2011

Journal Articles

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Dragana Milojkovic, MD, Amr R Ibrahim, Letizia Foroni, MD PhD, Claire Lucas, Gareth Gerrard, PhD, Lihui Wang, Richard M Szydlo, Richard E Clark, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Marco Bua, MD, Jiri Pavlu, Christos Paliompeis, Alistair Reid, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 1680.

https://doi.org/10.1182/blood.V118.21.1680.1680

Published: 2011

Journal Articles

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley, Dragana Milojkovic, Marco Bua, Richard Szydlo, Francois-Xavier Mahon, Kasia Kozlowski, Christos Paliompeis, Letizia Foroni, Jamshid S. Khorashad, Alex Bazeos, Mathieu Molimard, Alistair Reid, Katayoun Rezvani, Gareth Gerrard, John Goldman, David Marin

Blood (2011) 117 (14): 3733–3736.

https://doi.org/10.1182/blood-2010-10-309807

Published: 2011

Journal Articles

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

Mustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, Lihui Wang, Philippa C. May, Christos Paliompeis, Dragana Milojkovic, Valeria A. De Melo, Gareth Gerrard, John M. Goldman, Jane F. Apperley, Richard E. Clark, Letizia Foroni, Alistair G. Reid

Blood (2010) 116 (26): 6014–6017.

https://doi.org/10.1182/blood-2010-01-264234

Published: 2010

Includes: Supplemental data

Journal Articles

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Amr R. Ibrahim, Christos Paliompeis, Marco Bua, Dragana Milojkovic, Richard Szydlo, Jamshid S. Khorashad, Letizia Foroni, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, Francesco Dazzi, Jane F. Apperley, John M. Goldman, David Marin

Blood (2010) 116 (25): 5497–5500.

https://doi.org/10.1182/blood-2010-06-291922

Published: 2010

Journal Articles

Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

Alex Bazeos, Jamshid Khorashad, François-Xavier Mahon, Lina L Eliasson, Dragana Milojkovic, Marco Bua, Jane Apperley, Richard Szydlo, Kasia Kozlowski, Christos Paliompeis, Ritti Desai, Letizia Foroni, Alistair Reid, Hugues de Lavallade, Katy Rezvani, John Goldman, David Marin

Blood (2009) 114 (22): 3290.

https://doi.org/10.1182/blood.V114.22.3290.3290

Published: 2009

NARROW

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

Email alerts

ASH Publications

American Society of Hematology

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only